Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by Novo Nordisk A/S

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
From Novo Nordisk A/S
Via GlobeNewswire
Tickers B
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.